BridgeBio Pharma Research and Development Expenses 2018-2024 | BBIO
BridgeBio Pharma research and development expenses from 2018 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
BridgeBio Pharma Annual Research and Development Expenses
(Millions of US $) |
| 2023 |
$456 |
| 2022 |
$399 |
| 2021 |
$451 |
| 2020 |
$337 |
| 2019 |
$210 |
| 2018 |
$140 |
| 2017 |
$31 |
BridgeBio Pharma Quarterly Research and Development Expenses
(Millions of US $) |
| 2024-09-30 |
$120 |
| 2024-06-30 |
$115 |
| 2024-03-31 |
$141 |
| 2023-12-31 |
$130 |
| 2023-09-30 |
$125 |
| 2023-06-30 |
$107 |
| 2023-03-31 |
$93 |
| 2022-12-31 |
$91 |
| 2022-09-30 |
$93 |
| 2022-06-30 |
$108 |
| 2022-03-31 |
$108 |
| 2021-12-31 |
$122 |
| 2021-09-30 |
$104 |
| 2021-06-30 |
$102 |
| 2021-03-31 |
$123 |
| 2020-12-31 |
$90 |
| 2020-09-30 |
$92 |
| 2020-06-30 |
$87 |
| 2020-03-31 |
$68 |
| 2019-12-31 |
$57 |
| 2019-09-30 |
$55 |
| 2019-06-30 |
$52 |
| 2019-03-31 |
$45 |
| 2018-12-31 |
|
| 2018-09-30 |
$31 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
